moving immunotherapy to earlier lines in nsclc
Published 2 years ago • 227 plays • Length 2:22Download video MP4
Download video MP3
Similar videos
-
5:02
evaluating the lipi for first line immunotherapy in nsclc
-
1:30
immunotherapy in second-line treatment of non-small cell lung cancer
-
3:44
immunotherapy as combination and neoadjuvant therapies in nsclc
-
4:37
immunotherapy in early stage nsclc
-
2:43
clinical factors in the selection of patients for first-line immunotherapy of lung cancer
-
3:43
immunotherapy for operable lung cancer
-
1:20
pembro continues to demonstrate os benefit in first-line nsclc: keynote-024 update
-
2:08
using first-line immunotherapy in stage 4 nsclc
-
2:54
considerations for duration and de-escalation of immunotherapy in lung cancer
-
1:09
current and novel treatment approaches for first-line egfr-m nsclc
-
3:08
choosing immunotherapy as front line therapy for non-actionable nsclc
-
4:34
immunotherapy for first line therapy of advanced nsclc
-
1:02
early intervention neoadjuvant immunotherapy in lung cancer
-
1:53
dr. spigel on pembrolizumab/chemo combo in first-line nsclc
-
59:37
marking new milestones with immunotherapy in locally advanced and early lung cancer
-
1:51
future directions for neoadjuvant immunotherapy in lung cancer
-
0:47
the role of immunotherapy with kras inhibitors in kras-driven nsclc
-
3:25
moving immunotherapy and targeted therapies to the frontline setting
-
59:24
marking new milestones with immunotherapy in locally advanced and early lung cancer